Diakonie Klinikum Dietrich Bonhoeffer GmbH
- Address
- lock Available on a paid plan
Eye Diseases
At Diakonie Klinikum Dietrich Bonhoeffer GmbH, much of the clinical trial activity focuses on ophthalmology, especially age-related macular degeneration, geographic atrophy, diabetic retinopathy, and macular neovascularization. These studies are exploring new ways to slow vision loss, protect retinal function, and improve visual outcomes for people with progressive eye disease.
- Testing new treatments for diabetic retinopathy to improve retinal health and vision
- Evaluating therapies for geographic atrophy linked to age-related macular degeneration
- Studying approaches for dry AMD and related forms of retinal degeneration
- Assessing options for macular neovascularization to preserve sight
Overall, the site is contributing to research on both symptom control and disease modification in major retinal disorders.
Neoplasms
The cancer research portfolio at this hospital includes trials in rectal cancer, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma. The main goal is to evaluate whether newer treatment strategies can improve tumor control, support organ preservation, and extend the time patients remain free from disease progression.
- Investigating treatment strategies for intermediate and high-risk rectal cancer with a focus on preserving the rectum
- Testing new combinations for diffuse large B-cell lymphoma to improve response rates
- Studying therapies for relapsed or refractory CLL/SLL to delay progression and improve durability of response
These oncology studies reflect a strong interest in both solid tumors and blood cancers, with an emphasis on better treatment effectiveness and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 14d Molecular Therapeutics Inc.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diakonie Klinikum Dietrich Bonhoeffer GmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Aug 2019 | Jul 2025 |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 2 | Unknown | 2025-05-16 | 2025-11-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.